Olaparib: Phase III started

AstraZeneca started the double-blind, placebo-controlled, Phase III SOLO 1 (GOG-3004) trial to evaluate 300 mg oral olaparib twice daily for up to 2 years in about 344 BRCA-mutated ovarian cancer patients who are in complete or partial response following first-line, platinum-based chemotherapy. AstraZeneca is conducting the trial with the Gynecologic Oncology Group. AstraZeneca will use the BRACAnalysis test from Myriad Genetics Inc. (NASDAQ:MYGN, Salt Lake City, Utah) as a companion diagnostic to select patients likely to respond to olaparib (see BioCentury, June 17). ...